View Past PerformanceCell Source 대차대조표 건전성재무 건전성 기준 점검 0/6Cell Source 의 총 주주 지분은 $-20.1M 이고 총 부채는 $10.8M, 이는 부채 대 자기자본 비율을 -53.7% 로 가져옵니다. 총자산과 총부채는 각각 $292.4K 및 $20.4M 입니다.핵심 정보-53.72%부채/자본 비율US$10.82m부채이자보상배율n/a현금US$1.24k자본-US$20.14m총부채US$20.43m총자산US$292.45k최근 재무 건전성 업데이트공시 • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.모든 업데이트 보기Recent updates공시 • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 21Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer CenterCell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.공시 • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).공시 • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jul 22Cell Source, Inc. Announces Board ResignationsCell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company.공시 • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01Cell Source, Inc. announced delayed annual 10-K filingOn 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Mar 21USPTO Issues New Patents for Cell Source's Veto Cell TechnologyCell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.공시 • Mar 14Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical TrialsCell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD.공시 • Feb 26Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory BoardCell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.재무 상태 분석단기부채: CLCS 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.장기 부채: CLCS는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.부채/자본 비율 추이 및 분석부채 수준: CLCS 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.부채 감소: CLCS는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: CLCS 의 현재 여유 현금 흐름을 기준으로 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.예측 현금 활주로: CLCS 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 08:55종가2026/06/08 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cell Source, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Mar 29Cell Source, Inc. announced delayed annual 10-K filingOn 03/28/2025, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 21Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer CenterCell Source, Inc. shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes. Breakthrough Results for Safer and Effective Transplants Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight: Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells. Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients. These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology. Comparable Successes Demonstrate Market Potential The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for $12 billion and $9 billion, respectively, following successful clinical outcomes and regulatory approvals in similar areas of cellular therapy. These precedents highlight the significant financial upside for novel treatments that achieve distinctive clinical efficacy and regulatory milestones. With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of $100 billion, underscoring the vast commercial potential for Veto Cells to gain market traction as the platform advances through clinical trials. Pathway to Market and Competitive EdgeCell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.
공시 • Aug 15Cell Source, Inc. announced delayed 10-Q filingOn 08/14/2024, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 02Cell Source, Inc. announced delayed annual 10-K filingOn 04/01/2024, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 17Cell Source, Inc. announced delayed 10-Q filingOn 08/15/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.9m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$14.9k market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).
공시 • May 17Cell Source, Inc. announced delayed 10-Q filingOn 05/16/2023, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jul 22Cell Source, Inc. Announces Board ResignationsCell Source, Inc. announced that onJuly 18, 2022, each of Ben Friedman and David Zolty resigned his position as a director of the company.
공시 • May 13Cell Source, Inc. announced delayed 10-Q filingOn 05/12/2022, Cell Source, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01Cell Source, Inc. announced delayed annual 10-K filingOn 03/31/2022, Cell Source, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Mar 21USPTO Issues New Patents for Cell Source's Veto Cell TechnologyCell Source, Inc. announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. The first patent, "Veto Cells Generated from Memory T Cells", describes Veto Cells that safely elicit patient acceptance of transplanted cells, such as stem cells, by overcoming the barriers of graft rejection and graft versus host disease (GvHD). Veto Cells are also capable of fighting potential viral and bacterial infections and can treat unresponsive cancers or cancers where limited treatment options exist. The second patent, "Methods of Transplantation and Disease Treatment", describes an invention in which Veto Cells act as unique, powerful companion cells that allow cellular therapies such as CAR-T and NK to be safely tolerated by the patient without transplant rejection or graft vs. host disease (GvHD) – while increasing overall combined treatment impact. The patents describe Veto Cell inventions in which Veto Cells work in conjunction with existing stem cell transplant therapies to protect the patient from transplant-related complications while increasing overall treatment efficacy, as well as inventions in which Veto Cells have been exposed to third-party antigens, thereby enabling Veto Cells to work on their own to effectively target cancers that have not responded to genetically modified T-cell therapies or where these therapies do not currently exist.
공시 • Mar 14Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical TrialsCell Source, Inc. announced that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably prevent the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells. The study, correction of murine sickle cell disease by allogeneic hæmatopoietic cell transplantation with anti-3rd party veto cells, published online by BMT Journalon March 3, 2021. As noted in BMT Journal, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor's transplanted healthy cells begin to be produced by the recipient mice instead of the host defective cells) and prevent onset of SCD pathology by overcoming several significant challenges, including: the need for safer partially or fully mismatched bone marrow transplantation (BMT) protocols; the challenge of transplant rejection under reduced intensity conditioning (RIC); and the possibility of graft vs. host disease under RIC. A phase 1/2 clinical trial is currently in progress testing the safety and efficacy of the company’s Veto Cells in patients with hematological cancers or with non-malignant hematological diseases including SCD.
공시 • Feb 26Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory BoardCell Source, Inc. announced that Joseph Rosenthal has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA.